GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
-0.49%14.3214.2%$231.59m
SHPGShire PLC Sponsored ADR
-3.19%140.910.4%$206.03m
PRGOPerrigo Co. Plc
-0.34%77.016.4%$150.83m
MNKMallinckrodt Plc
-0.55%36.1917.7%$118.18m
UTHRUnited Therapeutics Corporation
0.53%129.7813.9%$87.09m
JAZZJazz Pharmaceuticals Plc
-0.36%143.882.2%$77.53m
ENDPEndo International Plc
-0.12%8.718.9%$70.98m
ALRAlere Inc.
0.48%49.792.7%$68.62m
HZNPHorizon Pharma plc
0.98%13.447.6%$66.81m
PRXLPAREXEL International Corporation
0.03%87.697.9%$66.09m
ICPTIntercept Pharmaceuticals, Inc.
0.32%104.4222.1%$61.21m
MYOKMyoKardia, Inc.
3.03%41.603.0%$48.86m
NDRMNeuroDerm Ltd.
0.20%38.633.6%$48.30m
PTLAPortola Pharmaceuticals, Inc.
1.22%54.658.9%$43.93m
MDCOMedicines Company
-0.09%35.4722.3%$41.16m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.